D-Leucine-d10

D-Leucine-d10 is the deuterium labeled D-Leucine. D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro[1].

Product Specifications

CAS Number

[271247-12-2]

Product Name Alternative

(R) -Leucine-d10

UNSPSC

12352211

Hazard Statement

H302-H315-H319-H335

Target

Endogenous Metabolite; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Metabolic Enzyme/Protease; Others

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Neurological Disease

Purity

99.80

Solubility

H2O : 1 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

[2H]C([2H])([2H])C(C([2H])([2H])[2H])([2H])C([2H])([2H])[C@](N)([2H])C(O)=O

Molecular Formula

C6H3D10NO2

Molecular Weight

141.23

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P362+P364-P405-P501

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Xiaoyu Cao, et al. Combination of PARP Inhibitor and Temozolomide to Suppress Chordoma Progression. J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193